Neil McFarlane
Chief Executive Officer at ZEVRA THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
Profile
Neil F.
McFarlane is currently the President, Chief Executive Officer & Director at Zevra Therapeutics, Inc. and an Independent Director at Collegium Pharmaceutical, Inc. Previously, he served as the Chief Executive Officer of Adamas Pharmaceuticals LLC and Adamas Pharmaceuticals, Inc. from 2019 to 2021.
He also held the position of Vice President at UCB, Inc. from 2011 to 2016 and Chief Operating Officer at Travere Therapeutics, Inc. from 2016 to 2019.
Mr. McFarlane obtained his undergraduate and graduate degrees from the University of Florida.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-05-15 | 49,365 ( 0.15% ) | 2 M $ | 2024-04-29 |
Neil McFarlane active positions
Companies | Position | Start |
---|---|---|
COLLEGIUM PHARMACEUTICAL, INC. | Director/Board Member | 2022-04-05 |
ZEVRA THERAPEUTICS, INC. | Chief Executive Officer | 2023-10-09 |
Former positions of Neil McFarlane
Companies | Position | End |
---|---|---|
Adamas Pharmaceuticals, Inc. | Chief Executive Officer | 2021-10-31 |
ADAMAS PHARMACEUTICALS, INC. | Chief Executive Officer | 2020-12-31 |
TRAVERE THERAPEUTICS, INC. | Chief Operating Officer | 2019-05-30 |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 2015-12-31 |
Training of Neil McFarlane
University of Florida | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
TRAVERE THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
Adamas Pharmaceuticals, Inc. |
- Stock Market
- Insiders
- Neil McFarlane